Tonix Pharmaceuticals (NASDAQ:TNXP) released its quarterly earnings data on Monday. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.01, Bloomberg Earnings reports.
Tonix Pharmaceuticals stock opened at $0.46 on Wednesday. The business has a fifty day simple moving average of $0.83. Tonix Pharmaceuticals has a 12 month low of $0.43 and a 12 month high of $15.70. The company has a market cap of $6.90 million, a price-to-earnings ratio of -0.02 and a beta of 1.54. The company has a current ratio of 9.54, a quick ratio of 9.54 and a debt-to-equity ratio of 0.01.
TNXP has been the subject of a number of analyst reports. Roth Capital raised Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Thursday, April 18th. ValuEngine lowered Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 17th.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.
Featured Article: Swap
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.